Peer-influenced content. Sources you trust. No registration required. This is HCN.
News Medical
Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.
Cardiology September 8th 2026
Medical Professionals Reference (MPR)
The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.
Cardiology September 2nd 2026
Medical News Today (MNT)
In a 10‑year cohort study, adults with irregular bedtimes and short sleep duration had nearly double the risk of heart attack or stroke, suggesting sleep timing may be a meaningful cardiovascular risk marker.
Cardiology April 21st 2026
Cardiology Advisor
MACE was identified in 121 of 4267 patients (2.8%), including all-cause death (1.3%), cardiovascular death (0.7%), nonfatal MI (0.5%), and hospitalization for unstable angina (1.0%).
Cardiology April 7th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS